Phagocyte extracellular traps in children with neutrophilic airway inflammation
- PMID: 34164555
- PMCID: PMC8215332
- DOI: 10.1183/23120541.00883-2020
Phagocyte extracellular traps in children with neutrophilic airway inflammation
Abstract
Childhood lung infection is often associated with prominent neutrophilic airway inflammation and excess production of proteases such as neutrophil elastase (NE). The mechanisms responsible for this inflammation are not well understood. One potentially relevant pathway is the production of extracellular traps by neutrophils (NETs) and macrophages (METs). The aim of this study was to measure NET and MET expression in children and the effect of deoxyribonculease (DNase) 1 and α1-antitrypsin (AAT) on this process. We studied 76 children (median age of 4.0 years) with cystic fibrosis or chronic cough who underwent investigational bronchoscopy. NETs, METs and neutrophil elastase activity in bronchoalveolar lavage (BAL) samples were measured using confocal microscopy and functional assays. The effects of DNase 1 and AAT on NET/MET expression and neutrophil elastase activity were examined in vitro. Both subject groups had airway neutrophilia with prominent BAL production of NETs with neutrophil elastase co-expression; the mean %±standard error of the mean of neutrophils expressing NETs in the cystic fibrosis group was 23.3±2.8% and in the non-cystic fibrosis group was 28.4±3.9%. NET expression was higher in subjects who had detectable neutrophil elastase activity (p≤0.0074). The percentage of macrophages expressing METs in the cystic fibrosis group was 10.7±1.2% and in the non-cystic fibrosis group was 13.2±1.9%. DNase 1 decreased NET/MET expression (p<0.0001), but increased neutrophil elastase activity (p≤0.0137). The combination of AAT and DNase 1 reduced neutrophil elastase activity (p≤0.0049). We observed prominent extracellular trap formation in symptomatic children with and without cystic fibrosis. This innate inflammatory response was down-regulated by a combination of currently available therapeutics.
Copyright ©The authors 2021.
Conflict of interest statement
Conflict of interest: P.T. King has nothing to disclose. Conflict of interest: L. Dousha has nothing to disclose. Conflict of interest: N. Clarke has nothing to disclose. Conflict of interest: J. Schaefer has nothing to disclose. Conflict of interest: R. Carzino has nothing to disclose. Conflict of interest: R. Sharma has nothing to disclose. Conflict of interest: K.L. Wan has nothing to disclose. Conflict of interest: A. Ananthrajah has nothing to disclose. Conflict of interest: K. O'Sullivan has nothing to disclose. Conflict of interest: Z.X. Lu has nothing to disclose. Conflict of interest: S.R. Holdsworth has nothing to disclose. Conflict of interest: S. Ranganathan has nothing to disclose. Conflict of interest: P.G. Bardin has nothing to disclose. Conflict of interest: D.S. Armstrong has nothing to disclose.
Figures




References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous